Roche RHHBY announced that the FDA has approved Polivy (polatuzumab vedotin-piiq) in combination with Rituxan (rituximab), cyclophosphamide, doxorubicin and prednisone (R-CHP) for the treatment of ...

The FDA indicated that it's reluctant to approve Roche's current application for Polivy in previously untreated large B-cell lymphoma. (Roche) When Roche touted data for Polivy in previously untreated ...

Roche Holding received FDA acceptance of Lunsumio VELO plus Polivy for relapsed or refractory large B cell lymphoma based on ...

Roche RHHBY announced that the FDA has accepted its supplemental biologics license application (sBLA) seeking approval of ...

Over the next five years, doctors expect to treat 36% of newly diagnosed diffuse large B-cell lymphoma patients with Roche's Polivy, a Jefferies survey shows. (Roche) () Roche Pharmaceuticals CEO Bill ...

Polivy is a type of targeted therapy called an antibody-drug conjugate. This antibody-drug conjugate is made up of an antibody that is attached to an anti-cancer medicine. Polivy is used to treat a ...

Lunsumio and Polivy showed an 88% overall response rate in relapsed/refractory MCL patients, with high efficacy in high-risk subgroups. The combination therapy was well-tolerated, despite a high ...

As with other drugs, Polivy (polatuzumab vedotin-piiq) can cause side effects, such as nausea, fatigue, and diarrhea. If side effects of Polivy become difficult to tolerate, talk with your doctor or ...

Credit: Genentech. Polivy is a CD79b-directed antibody and microtubule inhibitor conjugate. The Food and Drug Administration (FDA) has approved Polivy ® (polatuzumab vedotin-piiq) in combination with ...

The FDA has set aside reservations it had about the use of Roche’s Polivy as a first-line treatment with chemotherapy for diffuse large B-cell lymphoma (DLBCL), and cleared the new indication for the ...

(RTTNews) - Roche (RHHBY) said that the European Commission has granted approval of Polivy or polatuzumab vedotin in combination with MabThera or rituximab plus cyclophosphamide, doxorubicin, and ...

Polivy plus R-CHP is the first treatment regimen to significantly improve outcomes in previously untreated diffuse large B-cell lymphoma in more than 20 years, potentially transforming treatment for ...